Morgan Stanley maintained its Buy rating on Gilead Sciences and kept its price target at $168. The firm cited the company's growth outlook and the launch trajectory of Yeztugo as key factors, viewing Yeztugo as a medium-term growth driver. Gilead has raised its 2026 sales guidance for Yeztugo. Separately, the FDA accepted a supplemental New Drug Application for a 300 mg tablet version of Yeztugo for once-weekly oral HIV prevention, with a decision date of February 2, 2027. If approved, it would become the first long-acting oral PrEP treatment.
Gilead Sciences IncFDA accepted sNDA for 300mg tablet of Yeztugo for once-weekly oral HIV prevention, with potential to be first long-acting oral PrEP.
Morgan Stanley